Intraperitoneal Chemotherapy for Ovarian Cancer: Where Are We Now?

View More View Less
  • 1 From the Department of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, New York.

Patients with advanced epithelial ovarian cancer are conventionally treated with intravenous (IV) platinum- and taxane-based chemotherapy to try to eradicate residual disease after optimal cytoreductive surgery, resulting in a median overall survival of 49 months. The Gynecologic Oncology Group (GOG) conducted 3 large randomized, phase III clinical trials of intraperitoneal (IP) chemotherapy (GOG 104, 114, and 172) that clearly showed superior progression-free and overall survival with IP chemotherapy compared with IV chemotherapy. All 3 clinical trials investigated IP cisplatin, with the last one adding IP paclitaxel. The most recent study (GOG 172) resulted in a median survival of 66 months for patients in the IP arm versus 50 months for those in the IV arm. Fewer patients in the IP arm than in the IV arm completed all 6 treatment cycles (42% vs. 83%, respectively) because of the toxic effects of chemotherapy and IP catheter-related complications. Initially, patients in the IP arm reported significantly worse quality of life than those in the IV arm. However, at 12-month follow-up, the groups experienced no difference in quality of life, except that paresthesias were more likely to persist at moderate levels among patients in the IP arm. Based on these clinical trials, the National Cancer Institute issued a clinical announcement recommending that women with stage III ovarian cancer who undergo optimal surgical cytoreduction be considered for IP chemotherapy.

If the inline PDF is not rendering correctly, you can download the PDF file here.

Correspondence: Shashikant Lele, MD, Department of Gynecologic Oncology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263. E-mail: shashi.lele@roswellpark.org
  • 1.

    Jemal A, Murray T, Ward E. Cancer statistics, 2005. CA Cancer J Clin 2005;55:1030.

  • 2.

    McGuire WP, Hoskins WJ, Brady MF. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). Semin Oncol 1996;23:4047.

    • Search Google Scholar
    • Export Citation
  • 3.

    Ozols RF, Bundy BN, Greer BE. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003;21:31943200.

    • Search Google Scholar
    • Export Citation
  • 4.

    Hoskins WJ, McGuire WP, Brady MF. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 1994;170:974979; discussion 979–980.

    • Search Google Scholar
    • Export Citation
  • 5.

    Bristow RE, Tomacruz RS, Armstrong DK. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002;20:12481259.

    • Search Google Scholar
    • Export Citation
  • 6.

    Dedrick RL, Myers CE, Bungay PM. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 1978;62:111.

    • Search Google Scholar
    • Export Citation
  • 7.

    Cannistra SA. Cancer of the ovary. N Engl J Med 2004:351:25192529.

  • 8.

    Thigpen T. The if and when of surgical debulking for ovarian carcinoma. N Engl J Med 2004;351:25442546.

  • 9.

    Markman M. Intraperitoneal antineoplastic agents for tumors principally confined to the peritoneal cavity. Cancer Treat Rev 1986;13:219242.

    • Search Google Scholar
    • Export Citation
  • 10.

    Markman M, Francis P, Rowinsky E. Intraperitoneal paclitaxel: a possible role in the management of ovarian cancer? Semin Oncol 1995;22:8487.

  • 11.

    Howell SB, Pfeifle CL, Wung WE. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med 1982;97:845851.

  • 12.

    Lopez JA, Krikorian JG, Reich SD. Clinical pharmacology of intraperitoneal cisplatin. Gynecol Oncol 1985;20:19.

  • 13.

    Markman M, Francis P, Rowinsky E. Intraperitoneal Taxol (paclitaxel) in the management of ovarian cancer. Ann Oncol 5 1994;7[suppl 6]:S55S58.

    • Search Google Scholar
    • Export Citation
  • 14.

    Kirmani S, Braly PS, McClay EF. A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancer. Gynecol Oncol 1994;54:338344.

    • Search Google Scholar
    • Export Citation
  • 15.

    Alberts DS, Liu PY, Hannigan EV. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996;335:19501955.

    • Search Google Scholar
    • Export Citation
  • 16.

    Polyzos A, Tsavaris N, Kosmas C. A comparative study of intraperitoneal carboplatin versus intravenous carboplatin with intravenous cyclophosphamide in both arms as initial chemotherapy for stage III ovarian cancer. Oncology 1999;56:291296.

    • Search Google Scholar
    • Export Citation
  • 17.

    Gadducci A, Carnino F, Chiara S. Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest. Gynecol Oncol 2000;76:157162.

    • Search Google Scholar
    • Export Citation
  • 18.

    Yen MS, Juang CM, Lai CR. Intraperitoneal cisplatin-based chemotherapy vs. intravenous cisplatin-based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancer. Int J Gynaecol Obstet 2001;72:5560.

    • Search Google Scholar
    • Export Citation
  • 19.

    Markman M, Bundy BN, Alberts DS. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001;19:10011007.

    • Search Google Scholar
    • Export Citation
  • 20.

    Armstrong DK, Bundy B, Wenzel L. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:3443.

  • 21.

    McGuire WP, Hoskins WJ, Brady MF. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 1955;13:15891599.

    • Search Google Scholar
    • Export Citation
  • 22.

    Gore M, Mainwaring P, A'Hern R. Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology Group. J Clin Oncol 1998;16:24262434.

    • Search Google Scholar
    • Export Citation
  • 23.

    Jakobsen A, Bertelsen K, Andersen JE. Dose-effect study of carboplatin in ovarian cancer: a Danish Ovarian Cancer Group study. J Clin Oncol 1997;15:193198.

    • Search Google Scholar
    • Export Citation
  • 24.

    Conte PF, Bruzzone M, Carnino F. High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest. J Clin Oncol 1996;14:351356.

    • Search Google Scholar
    • Export Citation
  • 25.

    Dittrich C, Sevelda P, Salzer H. Lack of impact of platinum dose intensity on the outcome of ovarian cancer patients. 10-year results of a prospective randomised phase III study comparing carboplatin-cisplatin with cyclophosphamide-cisplatin. Eur J Cancer 2003;39:11291140.

    • Search Google Scholar
    • Export Citation
  • 26.

    Walker JL, Armstrong DK, Huang HQ. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol Oncol 2006;100:2732.

    • Search Google Scholar
    • Export Citation
  • 27.

    Wenzel LB, Huang HQ, Armstrong DK. Validation of a FACT/GOG-Abdominal Discomfort subscale: a Gynecologic Oncology Group study [abstract]. J Clin Oncol 2005;23:754s. Abstract 8101.

    • Search Google Scholar
    • Export Citation
  • 28.

    Wenzel LB, Huang HQ, Armstrong DK. Quality of life results of a randomized study of intravenous paclitaxel and cisplatin versus IV paclitaxel, intraperitoneal cisplatin and IP paclitaxel in optimal stage III epithelial ovarian cancer: a Gynecologic Oncology Group trial [abstract]. J Clin Oncol 2004;22. Abstract 5026.

    • Search Google Scholar
    • Export Citation
  • 29.

    Piccart MJ, Floquet A, Scarfone G. Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy. Int J Gynecol Cancer 2003;13[suppl 2]:196203.

    • Search Google Scholar
    • Export Citation
  • 30.

    Alberts DS, Markman M, Armstrong D. Intraperitoneal therapy for stage III ovarian cancer: a therapy whose time has come! J Clin Oncol 2002;20:39443946.

    • Search Google Scholar
    • Export Citation
  • 31.

    Makhija S, Leitao M, Sabbatini P. Complications associated with intraperitoneal chemotherapy catheters. Gynecol Oncol 2001;81:7781.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 134 52 12
PDF Downloads 123 58 10
EPUB Downloads 0 0 0